Skip to main content

Table 1 Patient characteristics

From: Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer

Patients, n

80

Age at MDT (years), median (range)

72 (50–87)

Initial tumor stage, n (%)

 T1

3 (3.8%)

 T2

21 (26.3%)

 T3

54 (67.5%)

 Unknown

2 (2.5)

Initial nodal stage, n (%)

 N0

51 (63.7%)

 N + 

21 (26.3%)

 Nx

5 (6.3%)

 Unknown

3 (3.8%)

Gleason score, n (%)

 ≤ 6

1 (1.3%)

 7

26 (32.5%)

 8

13 (16,3%)

 ≥ 9

40 (50.0%)

Initial PSA (ng/ml), median (range)

11,7 (3,6–1252)

Primary treatment, n (%)

 Surgery

39 (48.8%)

 Surgery + postoperative RT

25 (31.3%)

 Definitive RT

4 (5.0%)

 Primary ADT or chemotherapy

9 (11.3%)

 No pretreatment

3 (3.8%)

Time from primary treatment to MDT (months), median (range)

22.1 (0–260)

Category of oligometastatic disease, n (%)

 De novo synchronous oligometastatic disease

25 (31.3%)

 Metachronous oligorecurrent disease

37 (46.3%)

 Metachronous oligoprogressive disease

3 (3.8%)

 Induced oligometastatic disease

7 (8.8%)

 Repeat oligometastatic disease

8 (10.0%)

Previous ADT, n (%)

43 (53.8%)

HSPC/CRPC, n (%)

62 (77.5%)/18 (22.5%)

  1. ADT, androgen deprivation therapy; CRPC, castration-resistant prostate cancer; HSPC, hormone-sensitive prostate cancer; MDT, metastasis-directed therapy; PSA, prostate specific antigen; RT, radiotherapy